UNDERSTANDING VENTRICULAR REMODELING IN PATIENTS WITH CHRONIC HEART FAILURE

Authors

  • Rabia Nasir District Headquarter Teaching Hospital, MTI, Dera Ismail Khan-29050-Pakistan Author
  • Shahzad Rafiq Quaid-e-Azam Medical College, Bahawalpur, Punjab, Pakistan Author

Keywords:

Ventricular Remodelling, Chronic Heart Failure, Myocardial Fibrosis, Inflammation, Cardiac Hypertrophy, Heart Failure Biomarkers

Abstract

Ventricular remodelling is a critical determinant in the progression of chronic heart failure (CHF), encompassing a spectrum of structural, cellular, and molecular changes that impair cardiac function over time. This study offers a comprehensive investigation into the mechanisms underlying ventricular remodelling, with a particular emphasis on the interplay between inflammation, metabolic shifts, extracellular matrix alterations, and myocardial fibrosis. Our findings underscore that remodelling is initiated by primary cardiac insults such as ischemic injury or hypertensive stress, which trigger compensatory responses including cardiomyocyte hypertrophy and extracellular matrix expansion.Stimulating the heart for a long time can cause thickening of the chambers, hardening of the tissue, and both bulging and weakening of the heart.  We discovered that NF-κB and TGF-β govern collagen deposition and cellular responses of fibroblasts, which later contributes to scar formation and ventricular hardening.  The process from acute heart damage to eventual scarring in the far parts of the heart could be clearly seen in the investigation of phases of heart damage following a heart attack.  There is also a strong emphasis in the study on how obesity, diabetes, and COPD speed up diastolic dysfunction.  Scientists examined the usefulness of cardiac MRI, echocardiography, and measurements of NT-proBNP and troponin in assessing the extent of remodelling in the heart.  It appears that drugs such as beta-blockers and ACE inhibitors have helped to slow remodeling, but the disease’s fibrosis still progresses to some extent.  In addition, even though LVADs are helpful for patients with heart failure, they have a high chance of complications and hospitalizations.  This research suggests that developing tailored therapies to treat the inflammation and scarring in CHF is necessary.  More effective treatments for stopping or reversing remodelling in the heart may be developed based on a better understanding of these pathways.

Downloads

Published

2025-06-30